Bayer HealthCare to build biologicals facility in Wuppertal, Germany

Main focus of Bayer HealthCare is on antibodies, coagulation factors and other therapeutic proteins

Bayer HealthCare is investing EUR35m to build a new facility center in Wuppertal, Germany, for the biotechnological production of pharmaceuticals to be used in clinical trials.

The main focus of Bayer HealthCare is on antibodies, coagulation factors and other therapeutic proteins.

According to Bayer the building will be a multipurpose facility with great flexibility, in which 20 highly qualified members of staff will manufacture a variety of products.

The new facility will go into operation in late 2012.

Bayer HealthCare Executive Committee member Andreas Busch said the new facility center will enable them to increase production capacities to manufacture enough material for the late phases in clinical development for an increased number of potential active ingredients.

Bayer HealthCare Wuppertal location manager Klaus Jelich said from research and development to the production of active substances, they cover all important disciplines - namely those related to chemical and biological active ingredients.